| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Idarucizumab |
| Brand | Praxbind® |
| Indication | As a specific reversal agent for dabigatran in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required: for emergency surgery/urgent procedures or life-threatening or uncontrolled bleeding. |
| Assessment Process | |
| Rapid review commissioned | 11/12/2015 |
| Rapid review completed | 18/12/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
